RecruitingNCT03275311

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Database: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008

Sponsor

UNICANCER

Enrollment

42,000 participants

Start Date

Jul 1, 2014

Study Type

OBSERVATIONAL

Conditions

Metastatic Breast Cancer

Summary

The Epidemiological Strategy and Medical Economic (ESME) Breast cancer Database is a multicenter real life database using a retrospective data collection process across 18 French comprehensive cancer centers (FCCC) spread over 20 sites. This database compiles data from patient's electronic medical records (EMR).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is tracking how treatments for metastatic breast cancer (breast cancer that has spread to other parts of the body) have changed since 2008, and how those changes have affected patient outcomes over time at cancer centers in France. **You may be eligible if...** - You are 18 years or older - You are receiving treatment for metastatic breast cancer (chemotherapy, targeted therapy, immunotherapy, radiation, or hormone therapy) at a French Comprehensive Cancer Center **You may NOT be eligible if...** - There are no specific exclusion criteria listed for this study — it is broadly open to patients meeting the above description Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(20)

Institut de Cancérologie de l'Ouest - Paul Papin

Angers, France

Institut Bergonié

Bordeaux, France

Centre François Baclesse

Caen, France

Centre Jean Perrin

Clermont-Ferrand, France

Centre Georges-François Leclerc

Dijon, France

Centre Oscar Lambret

Lille, France

Centre Léon Bérard

Lyon, France

Institut Paoli-Calmettes

Marseille, France

Institut régional du Cancer Montpellier / Val d'Aurelle

Montpellier, France

Institut de Cancérologie de Lorraine

Nancy, France

Institut de cancérologie de l'Ouest - René Gauducheau

Nantes, France

Centre Antoine Lacassagne

Nice, France

Institut Curie

Paris, France

Institut Jean Godinot

Reims, France

Centre Eugène Marquis

Rennes, France

Centre Henri Becquerel

Rouen, France

Institut Curie - Hôpital René Huguenin

Saint-Cloud, France

Centre Paul Strauss

Strasbourg, France

Institut Claudius Regaud

Toulouse, France

Institut Gustave Roussy

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03275311

Related Trials

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT0612028363 locations

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

NCT066782697 locations

Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers

NCT072527263 locations

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357108 locations

Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer

NCT069046251 location